Hormonal
Administration of the bioactive peptide adropin34-76 improves glucose tolerance and insulin sensitivity in diet-induced obese mice by enhancing skeletal muscle insulin signaling and shifting fuel preference toward glucose oxidation.
This research suggests that the peptide hormone adropin can improve how the body processes glucose and insulin in obese individuals. It works by enhancing insulin signaling in muscles and shifting the body's fuel preference from fat to glucose. While this is a peptide therapy not yet available for general use, it highlights the importance of hormonal balance in metabolic health and offers a potential future therapeutic avenue for insulin resistance.
Adropin treatment improved glucose tolerance, enhanced insulin action and augmented metabolic flexibility towards glucose utilization... Adropin treatment of DIO mice enhances glucose tolerance, ameliorates insulin resistance and promotes preferential use of carbohydrate over fat in fuel selection.
Why this rating
The study is a controlled animal model (DIO mice) with clear biochemical and physiological endpoints, but results may not directly translate to humans without further clinical trials.
Source
Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance
Su Gao et al. · Molecular Metabolism · 2015
DOI 10.1016/j.molmet.2015.01.005
More from this paper
- Adropin34-76 treatment reduces incomplete fatty acid oxidation and increases the CoA/acetyl-CoA ratio in skeletal muscle, indicating improved mitochondrial function in obese mice.Moderate
- Adropin34-76 treatment activates pyruvate dehydrogenase (PDH) and downregulates PDH kinase-4 (PDK-4) in skeletal muscle, promoting glucose oxidation in obese mice.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →